Ardelyx (ARDX) Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARDX shares.
View ARDX analyst ratings or view top-rated stocks.

6 Wall Street analysts have issued 1 year price objectives for Ardelyx's stock. Their ARDX share price forecasts range from $7.00 to $10.00. On average, they anticipate the company's share price to reach $8.25 in the next twelve months. This suggests a possible upside of 125.4% from the stock's current price.
View analysts price targets for ARDX or view top-rated stocks among Wall Street analysts.

Ardelyx's stock was trading at $2.85 at the beginning of 2023. Since then, ARDX stock has increased by 28.4% and is now trading at $3.66.
View the best growth stocks for 2023 here.

Ardelyx saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 25,770,000 shares, a decline of 7.1% from the August 15th total of 27,750,000 shares. Based on an average daily volume of 5,150,000 shares, the days-to-cover ratio is currently 5.0 days.
View Ardelyx's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our ARDX earnings forecast.

Ardelyx, Inc. (NASDAQ:ARDX) released its quarterly earnings data on Wednesday, August, 2nd. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.04. The biopharmaceutical company had revenue of $22.33 million for the quarter, compared to analyst estimates of $15.88 million. Ardelyx had a negative trailing twelve-month return on equity of 54.22% and a negative net margin of 67.69%.

ETFs with the largest weight of Ardelyx (NASDAQ:ARDX) stock in their portfolio include SPDR S&P Biotech ETF (XBI) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Direxion Daily S&P Biotech Bull 3x Shares (LABU).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD) and Advanced Micro Devices (AMD).

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Ardelyx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include State Street Corp (10.30%), BlackRock Inc. (6.44%), Geode Capital Management LLC (1.94%), Intrinsic Edge Capital Management LLC (1.13%), Woodline Partners LP (1.10%) and Northern Trust Corp (0.90%). Insiders that own company stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, Justin A Renz, Laura A Williams, Michael Raab, Robert Blanks, Robert Ora Felsch, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends.

Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARDX stock can currently be purchased for approximately $3.66.

Ardelyx (NASDAQ:ARDX) has a market capitalization of $797.37 million and generates $52.16 million in revenue each year. The biopharmaceutical company earns $-67,210,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis.

The company employs 133 workers across the globe.

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The official website for the company is www.ardelyx.com. The biopharmaceutical company can be reached via phone at (510) 745-1700, via email at investor@ardelyx.com, or via fax at 510-745-0493.